Issue of Equity

Bioventix plc                                 

                        ("Bioventix" or the "Company")                         

                                Issue of Equity                                

Bioventix plc (AIM: BVXP) announces that it has today applied for 6,729
ordinary shares of 5 pence each (the "Option Shares") to be admitted to trading
on AIM ("Admission"). It is expected that Admission will occur and that
dealings will commence in the Option Shares on 14 November 2014.

The Option Shares are being issued pursuant to the exercise of options by a
former employee of the Company. The Option Shares will rank pari passu with the
existing ordinary shares of 5 pence each in the capital of the Company
("Ordinary Shares").

The total number of Ordinary Shares in issue following Admission will be
5,050,931 and the Company holds no shares in treasury. Therefore the total
number of Ordinary Shares with voting rights in the Company is 5,050,931.

The above figure of 5,050,931 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, Bioventix under the
FCA's Disclosure and Transparency Rules.

For further information please contact:

Bioventix plc              Chief Executive Officer    Tel: [phone]       
Peter Harrison                                                                 
                                                                               
finnCap Ltd                Corporate Finance          Tel: [phone]       
Geoff Nash/Simon Hicks     Corporate Broking                                   
Stephen Norcross                                                               

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce a
suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.